Galmed's stock rock­ets up as ex­ecs tout a mixed set of NASH da­ta

Shares of yet an­oth­er NASH hope­ful are rock­et­ing north this morn­ing, with Tel Aviv-based Galmed post­ing news on its Phase IIb fat­ty liv­er dis­ease drug. Al­though the da­ta are ex­cit­ing some in­vestors, the re­sults were al­so dis­tinct­ly mixed, rais­ing some doubts about the sud­den en­thu­si­asm.

The com­pa­ny, which re­port­ed a flop for the roll­out of its last NASH tri­al, to­day re­port­ed top-line, 52-week re­sults from a glob­al study test­ing its drug Aram­chol in a high dose (600 mg) and low­er dose (400 mg), along­side a place­bo. The goal was to cut down liv­er fat, with the sec­ondary end­points shoot­ing for a re­duc­tion in scar­ring (fi­bro­sis) and NASH res­o­lu­tion. The low­er dose met the pri­ma­ry end­point, the com­pa­ny said, post­ing a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion in liv­er fat vs. place­bo (p=0.0450). The high dose did not.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN